Loading...

ARDX ARDELYX INC Contract Awards 8-K Filing

RDLY

RDX

ARDELYX INC

(ARDX)

2024 8-K

Financial Results Update

Financial Update

Management Changes

Financial Results Released

Leadership Change

Debt-Equity Swaps

Financial Statements

Financial Results

Q4 Earnings Report

Management Change

Financial Results

New Lease Agreement

Supply Agreement

Earnings Reports

Approval of Amendment and R...

Earnings Reports

Funding Received

Financial Results Announcement

Financial Results

Resignation of Director

Financial Results Announcement

Loan Agreement Amendment

Other Special Situation

Financial Results Announcement

Amendment to Increase Autho...

FDA Accepts Resubmission of...

Financial Results Announcement

Financial Results Announcement

Loan Agreement Amendment

Agreement with Jefferies LLC

External Links:

Ardelyx, Inc. has entered into a Commercial Supply Agreement with Catalent Pharma Solutions for the manufacturing of IBSRELA, effective July 23, 2024, with a minimum batch purchase commitment and annual price adjustments based on the producer price index, lasting until December 31, 2028.

AI Assistant

ARDELYX INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.